Loss of heterozygosity (LOH) at 6q16-22 and 10q22.3-23.1 is common chromosomal alteration in advanced prostate cancer and suggests that one or more tumor suppressor genes may lie within these chromosome arms. However, the genetic changes in early stage prostate cancer and premalignant lesions remain to be investigated. We used 11 informative microsatellite markers at 6q16-22 and 10q22.3-23.1 in Japanese patients to compare the frequency of LOH in 53 lesions of high-grade prostatic intraepithelial neoplasia (HGPIN), 38 cases (38 lesions) of incidental prostate cancer (IPC) and 107 cases (168 lesions) of clinical prostate cancer (CPC). The frequency of LOH at 6q16-22 with at least one marker was 38 and 49% in IPC and CPC cases, respectively. Similarly, allelic loss at 10q22.3-23.1 was present in 35 and 39% of IPC and CPC, respectively. High-frequency LOH was detected in both the clinically insignificant and significant prostate cancers at 6q16-22 and 10q22.3-23.1 (P40.05). However, no allelic loss was detected in any markers at the same regions in HGPIN (0%), which is usually considered a premalignant lesion to prostate cancer. Deletions of both the chromosome regions, 6q16-22 and 10q22.3-23.1, are more likely important events in the initiation and/or promotion of prostate cancer.
Background
Prostate cancer is the most common malignancy and second leading cause of cancer-related death in Western industrialized countries. According to a recent report, the number of new cases diagnosed as prostate cancer has risen to 230 110 annually, and is expected to continue to increase. 1 In Japan, although the incidence of clinical prostate cancer (CPC) is still relatively low, that of incidental prostate cancer (IPC), which is 'clinically insignificant' prostate cancer, is similar to rates in Western countries. 2, 3 Most IPCs are detected incidentally when specimens obtained at cystoprostatectomy for bladder carcinoma are subjected to pathological examination. The reported incidence of prostate cancer in cystoprostatectomy specimens is 40% and 30% of these tumors are considered IPC. [4] [5] [6] [7] We found that almost the same incidence (B28%) of IPC was detected in Japanese patients (unpublished data). These data suggest that a large proportion of prostate cancers are clinically indolent and that only a minority of men with a histological diagnosis of prostate cancer will develop clinically significant, life-threatening tumors. 8, 9 Histological findings have suggested that clinically insignificant prostate cancer is an early phase of clinically significant prostate cancer. 10 However, at present it remains unclear what is the difference in carcinogenesis between IPC and CPC.
Numerous studies have shown that the initiation and/ or promotion and subsequent development of prostate cancer are complex processes that involve multiple genetic abnormalities. Notably, the inactivation of tumor suppressor genes (TSGs) through allelic loss is thought to be an important mechanism of gene alteration in prostate cancer. Array-based comparative genomic hybridization and single-nucleotide polymorphism microarray studies have shown that loss of some chromosomal arms, such as 13q14, 8p22, 6q16 and 10q23, is frequently detected in advanced human cancers. [11] [12] [13] Deletions of the long arms of chromosomes 6 and 10 have been identified in several human cancers, including pheochromocytoma, 14 bladder cancer, 15 lymphoma, 16 leiomyosarcoma 17 and hepatocellular carcinoma, 18 as well as prostate cancer. 19, 20 Altogether, these results indicated that loss of 8p22, 13q14, 6q16 and 10q23 is more frequent in advanced prostate cancer; however, little is known about the genetic mechanisms underlying the progression from the universal precursor to clinically insignificant or significant prostate cancer. Therefore, the characterization of clinically insignificant prostate cancer and its precursor would help to clarify the mechanisms of prostatic carcinogenesis. To obtain a comprehensive view of the loss of heterozygosity (LOH) at 6q16-22 and 10q22.3-23.1, which might potentially be involved in the tumorigenesis of prostate cancer, we compared the LOH frequency in IPC, CPC and high-grade prostatic intraepithelial neoplasia (HGPIN), which is usually adjacent to a tumor and thought to be a universal precursor to prostate cancer, by using 11 informative microsatellite markers in Japanese men at the two of the most frequent deletion regions, 6q16-22 and 10q22.3-23.1.
Materials and methods

Tissue collection and histopathology
A total of 247 cancerous lesions from 176 cases of prostate cancer and 53 HGPIN lesions were used in this study. Of these, 38 were IPC lesions obtained from tissues resected during 38 cystoprostatectomies, and 168 were CPC lesions that were obtained, along with the 53 HGPIN lesions, from tissues resected during 107 radical prostatectomies. In this study, none of the patients with IPC had any evidence of prostate cancer before cystoprostatectomy. All IPC samples have a low tumor volume (o100 mm 3 ) and at low prostate-specific antigen levels of 0-3.9 ng ml À1 . The tumor volumes of the IPCs were measured as previously reported. 21, 22 All specimens were formalin-fixed and paraffin-embedded tissues were processed with routine histological methods. Use of the tissues was approved by the ethics committee of the Jikei University School of Medicine before the study.
The tumors were classified according to the Gleason grading system before collection. Patterns of tumor growth were graded 1-5 according to increasing histological malignancy. In each case, predominant and secondary patterns were recorded as a Gleason score ranging from 2 to 10. In this study, tumors with a Gleason score of 4-7, corresponding to Gleason grades 2 and 3, were classified as low-to intermediate-grade tumors, and tumors with a Gleason score of 8-10, or Gleason grades 4 and 5, were classified as high-grade tumors. HGPIN lesions were collected from enlarged epithelial cells with marked variation in nuclear size and frequently with nucleoli. Tumors and HGPIN lesions were paired with surrounding morphologically normal tissues from the same patients.
DNA extraction
The tumor and corresponding noncancerous areas and normal tissues were microdissected from 10 mm tissue specimens. Microdissected tissues were placed in sterile Eppendorf tubes containing 400 ml of digestion buffer (50 mM Tris-HCl (pH 8.0); 0.5% sodium dodecyl sulfate and 500 mg ml À1 protease K), and heated at 52 1C until the tissues were completely digested. Following a standard series of phenol/chloroform extractions, DNA samples were prepared. 21, 22 Matched tumors, HGPINs and normal specimens from IPCs and CPCs were analyzed for LOH by amplification of polymorphic microsatellite markers using the polymerase chain reaction (PCR). Eleven microsatellite markers at 6q16-22 and 10q22.3-23.1 were used. Detailed information for each marker was obtained from the Genome Database (Table 1) .
PCR analysis
DNA amplification was performed in 10 ml volumes containing 100 ng of genomic DNA as a template. Each PCR mixture contained 1.5 mM MgCl 2 ; 1 mM forward and reverse primers; 200 mM each of dATP, dGTP, dTTP and dCTP; 10 mCi of [a- Takara, Tokyo, Japan). PCR product (10 ml) was denatured with 30-60 ml of dye solution (95% formamide, 10 mM EDTA (pH 8.0), 0.2% xylene cyanol FF and 0.02% bromophenol blue) at 95 1C for 3 min and then cooled on ice immediately. Denatured product (3 ml) was separated on a 6% urea formamide-polyacrylamide gel and electrophoresed at 40 W for 2-3 h at room temperature. The dried gels were exposed to Hyperfilm MP (Amersham Biosciences Corp.) for 3-7 days and reexposed to another film for 2-3 weeks.
Criteria for LOH
A pair of regular and longer-exposed autoradiographs was reviewed independently by us. Informative pairs LOH associated with initiation of prostate cancer T Lu and H Hano were judged by visual inspection to show LOH, to show no loss or to be uninformative. LOH was defined as loss of intensity of X60% in one or more alleles in the tumor or HGPIN tissue compared with the identical allele in the morphologically normal tissues (Figure 1 ). The differences in frequency of LOH between IPCs and CPCs for individual markers and background values were determined with Fisher's exact test.
Results
The distribution of the frequency of LOH at 6q16-22 and 10q22.3-23.1 for IPC and CPC is summarized in Table 2 . Allelic loss at 6q16-22 was detected with at least one marker in 38 and 49% of IPC and CPC cases, respectively. The frequency of LOH for each marker in the informative IPC cases or lesions ranged from 0 to 31% with an average of 18.7 ± 9.4% (mean ± s.d.). When mean percentage or more of the tumors from informative cases or lesions showed LOH, we classified the frequency of LOH at the locus as high. Therefore, the frequency of LOH at D6S1580, D6S261, D6S1706 and D6S287 markers was slightly higher in IPC. Simultaneously, the frequency of LOH for each marker in the informative CPC cases ranged from 8 to 31%, with an average of 22±8.2%. We found that allelic loss at D6S1543 and D6S283, which were located beside the high-frequency markers D6S1580 to D6S287 in IPC, was higher in CPC than in IPC, however, no statistical signification was found. Similarly, allelic loss at 10q22.3-23.1 was present in 35 and 39% of IPC and CPC, respectively. The frequency of LOH for each marker in the IPC ranged from 6 to 23% with an average of 16.7±7.8%. The frequency of allelic loss at each marker in CPC cases ranged from 6 to 29% with an average of 19±9.9%. The same result was obtained in the informative lesion-to-lesion comparison. Altogether, high frequency of LOH at 6q16-22 and 10q22.3-23.1 was detected in both clinically insignificant and significant prostate cancers. However, no allelic loss We also compared the frequency of LOH at 6q16-22 and 10q22.3-23.1 based on the pT category of the TNM classification. In this staging system, IPC is classified as pT1, and CPC is classified as pT2, pT3 or pT4. The frequency of LOH at 6q16-22 in pT1, pT2, pT3 and pT4 was 38, 47, 43 and 69%, respectively. Although the frequency of LOH at 6q16-22 was slightly higher in pT4 stage tumors than in the others, no significant difference was detected (P40.05). On the other hand, the frequency of LOH at 10q22.3-23.1 at each stage was 35, 37, 39 and 33%, respectively. No statistically significant difference was found between the tumors of each pT stage. A similar result was obtained for the frequency of LOH at 6q16-22 and 10q22.3-23.1 based on pT stage.
Correlations between LOH frequency and clinicopathological variable are summarized in Table 3 . Corresponding to the result described above, the LOH frequency tended to be higher at 6q16-22 in cases of tumors with lymph node metastasis than in cases without lymph node metastasis, but no significant difference was found (64 vs 44%, P40.05). No significant difference in LOH frequency was found on the basis of almost all of the clinicopathological findings of CPCs at 6q16-22 and 10q22.3-23.1. In other words, no association was detected between the deletion of 6q16-22 or 10q22.3-23.1 and subsequent progression of CPC.
Discussions
Allelic loss of 6q16-22 and 10q22.3-23.1, common chromosomal alteration in advanced prostate cancer, suggests that one or more TSGs lie within these chromosomal arms. However, the genetic changes in the earlier stages of prostate cancer and premalignant lesions remain to be investigated. In this study, we first compared the frequency of LOH at 6q16-22 and 10q22.3-23.1 in HGPIN, IPC and CPC.
We found allelic loss at 6q16-22 and 10q22.3-23.1 with a similarly high frequency in IPC and CPC but not in HGPIN, which is usually adjacent to cancerous lesions and assumed to be a precancerous form of prostate cancer. These results suggest that deletion of 6q16-22 and 10q22.3-23.1 is an important event in the initiation and/or promotion of prostate cancer.
The frequency of LOH at 6q16-22 and 10q22.3-23.1 in tumors with Gleason scores of 8-10, or Gleason grades of 4 and 5 was almost the same as that in tumors with Gleason scores of 4-7, or Gleason grades of 2 and 3. Moreover, no significant difference in the frequency of LOH at 6q16-22 and 10q22.3-23.1 was found based on most of the clinicopathological characteristics of CPC (Table 3 ). These findings suggest that deletion of chromosome regions, 6q16-22 and 10q22.3-23.1, is more LOH associated with initiation of prostate cancer T Lu and H Hano likely to play an important role in the initiation and/or promotion of prostate cancer, but not in the subsequent progression including metastasis. The LOH at 6q16-22 and 10q22.3-23.1 tended to differ from the results of our previous allelotyping at 8p and 13q in the same samples and another type of human cancer. [21] [22] [23] [24] These results led us to suggest that LOH at 6q16-22 and 10q22.3-23.1 might not be a newly occurring genetic change during the progression from early stage prostate cancer to clinical significant prostate cancer even in the metastatic stage. Previously, we had performed a genome-wide search for LOH with human genetic markers in several types of cancer and confirmed that chromosomal alterations, especially deletions of some restricted regions, such as 8p22-23.1 and 13q14, are not only related with the initiation but also closely associated with subsequent progression of human cancers, especially in the metastasis of primary tumors. 21, 22 The LOH at 6q16-22 and 10q22.3-23.1 tended to differ from the results of our previous allelotyping at 8p and 13q in the same samples.
Conclusions
Deletions of both the chromosomal regions, 6q16-22 and 10q22.3-23.1, are more likely important events in the initiation and/or promotion of the prostate cancer. Our results strongly suggest that some unknown critical genes may lie within the frequently deleted chromosomal regions, 6q16-22 and 10q22.3-23.1, which might be closely associated with the carcinogenesis of prostate cancer.
